High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study - Archive ouverte HAL Access content directly
Journal Articles Clinical and Experimental Medicine Year : 2022

High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study

(1) , (2, 3) , (4) , (5) , (6, 7) , (1) , (2, 3) , (2, 3) , (1, 8) , (9) , (10, 11) , , , , , , , , , , , , , , , , , , , , , , , , , ,
1
2
3
4
5
6
7
8
9
10
11
Antoine Touzé
G. Agius
  • Function : Author
S. Albert
  • Function : Author
E. Babin
  • Function : Author
J. Badet
  • Function : Author
C. Badoual
  • Function : Author
A. Baglin
  • Function : Author
K. Blanc-Fournier
  • Function : Author
E. Cassagneau
  • Function : Author
C. Debry
  • Function : Author
D. de Raucourt
  • Function : Author
M. Diebold
  • Function : Author
X. Dufour
  • Function : Author
M. Hourseau
  • Function : Author
R. Lacave
  • Function : Author
E. Lechapt Zalcman
  • Function : Author
M. Lefevre
  • Function : Author
P. Levillain
  • Function : Author
O. Malard
  • Function : Author
O. Mauvais
  • Function : Author
A. Mechine
  • Function : Author
J. Merol
  • Function : Author
H. Mirghani
  • Function : Author
S. Morinière
  • Function : Author
S. Périé
  • Function : Author
C. Rousselot
  • Function : Author
T. Simon
  • Function : Author

Abstract

The incidence of oropharyngeal cancers (OPC) is increasing in the world. Among OPC, those induced by human papillomaviruses have a better prognosis than non-HPV-associated OPC. The objective of this study was to highlight the relevance of HPV16 load, HPV16 DNA integration and HPV16-L1 serology on progression-free survival and overall survival of OPC patients. The PAPILLOPHAR cohort consists of 362 patients with oropharyngeal squamous cell carcinomas prospectively followed up for 5 years after treatment. Tumor biopsies and sera were collected at inclusion to investigate tumor HPV DNA/RNA characteristics and HPV16 L1 serology, respectively. Twenty-seven percent of tumor biopsies were HPV DNA- and RNA-positive and HPV16 represented 93% of HPV-positive cases. Among them, neither HPV16 viral load nor HPV16 DNA integration was associated with overall survival (OS) or progression-free survival (PFS). In contrast, high anti-HPV16 L1 antibody titers were significantly associated with a better OS and PFS. This study reveals that HPV16 load and integration are not relevant prognosis biomarkers in OPC patients. Clinical Relevance: High levels of HPV16 L1 antibodies may be useful to predict OPC patient outcome following treatment. ClinicalTrials.gov Identifier: NCT00918710, May 2017.
Not file

Dates and versions

hal-03603889 , version 1 (10-03-2022)

Identifiers

Cite

Jean-Luc Prétet, Véronique Dalstein, Antoine Touzé, Agnès Beby-Defaux, Patrick Soussan, et al.. High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study. Clinical and Experimental Medicine, 2022, ⟨10.1007/s10238-022-00796-2⟩. ⟨hal-03603889⟩
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More